ANIP News and Press, ANI Pharmaceuticals Inc. From 08/09/23

Second Quarter 2023 Financial Results -- Record quarterly net revenues of $116.5 million, representing year-over-year growth of 57.8%; net income available to common shareholders of $5.8 million and diluted GAAP income per share of $0.29 -- -- Record quarterly adjusted non-GAA...

2023-08-08 14:52:50 ET ANI Pharmaceuticals ( NASDAQ: ANIP ) is scheduled to announce Q2 earnings results on Wednesday, August 9th, before market open. The consensus EPS Estimate is $0.67 (+415.4% Y/Y) and the consensus Revenue Estimate is $99.86M (+35.1% Y/Y). Over the...

BAUDETTE, Minn., July 31, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2023 financial results on Wednesday, August 9, 2023, prior to the market open. Ni...

2023-07-05 00:51:54 ET Summary ANIP Pharmaceuticals has not yet published a pipeline of products under development or out-licensed, leaving investors in the dark about future revenue opportunities. The company has a range of drugs in various stages of development, including treatm...

2023-05-30 21:12:20 ET Summary ANI Pharmaceuticals exceeded Q1 Non-GAAP earnings expectations and raised its guidance to $385-$410 million. The company has a diverse product portfolio and strong relationships in the generic drug market. Despite high debt levels, ANI Pharmaceut...

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) today announced the closing of its previously announced underwritten public offering. A total of 2,183,545 shares of its common stock were sold at a public offering price of $39.50 per share, inclusive o...

2023-05-15 07:15:14 ET Shares of ANI Pharmaceuticals ( NASDAQ: ANIP ) spiked in the pre-market Monday after announcing that the FDA approved the market entry of the company’s generics for seizure therapy Celontin and osteoporosis drug RLD Fosamax Oral Solution. In approvi...

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Applications (ANDAs) for Methsuximide Capsules USP, 300 mg and Alendronate Sodium Oral Solution 70 mg (base)/75 mL. Methsuxi...

2023-05-12 07:37:34 ET ANI Pharmaceuticals ( NASDAQ: ANIP ) prices public offering of 1.9M shares at a public offering price of $39.50 per share. Gross proceeds are expected to be $75M. Underwriters a 30-day option to purchase up to an additional 284.8K shares. ...

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the "Company") today announced the pricing of its previously announced underwritten public offering of 1,898,735 shares of its common stock at a public offering price of $39.50 per share. The gross proceeds of the offering to the Co...